Astellas v. Renata: Myrbetriq® Generic Patent Dispute Settled in 68 Days

Introduction: A Swift Resolution in Pharmaceutical Patent Litigation

In a patent infringement action that concluded in just 68 days, Astellas Pharma, Inc. v. Renata Limited (Case No. 1:25-cv-01383, D. Del.) offers a textbook illustration of how branded pharmaceutical companies defend exclusivity through multi-patent assertion strategies — and how quickly those disputes can resolve when both sides find common ground.

Filed in Delaware District Court on November 14, 2025, and closed January 21, 2026, the case centered on Renata Limited’s proposed generic version of Myrbetriq® (mirabegron) extended-release tablets in 25 mg and 50 mg strengths. Astellas asserted four U.S. patents covering the formulation. The matter resolved via a negotiated Settlement and License Agreement, with all claims dismissed without prejudice and each party bearing its own costs.

For patent attorneys, IP professionals, and pharmaceutical R&D teams, this case reflects important trends in ANDA-related Hatch-Waxman patent litigation — including the strategic use of patent portfolios, the primacy of Delaware as a venue, and the growing frequency of pre-trial settlements.

Case Overview

The Parties

The Patents at Issue

Astellas asserted four U.S. patents, each targeting distinct aspects of the Myrbetriq® formulation. These patents collectively cover formulation, extended-release mechanism, and related pharmaceutical technology underlying Myrbetriq® tablets — a multi-layer defensive portfolio typical of branded drug protection strategies.

• • U.S. Patent No. 10,842,780 (App. No. 15/432,854)
• • U.S. Patent No. 11,707,451 (App. No. 17/114,890)
• • U.S. Patent No. 12,059,409 (App. No. 18/613,270)
• • U.S. Patent No. 12,097,189 (App. No. 18/613,281)

The Accused Product

The accused product was Renata’s proposed generic mirabegron extended-release tablets in 25 mg and 50 mg strengths — direct equivalents of the commercially available Myrbetriq® doses. The infringement action was triggered by Renata’s Abbreviated New Drug Application (ANDA) submission, a standard pathway under the Hatch-Waxman Act for bringing generic drugs to market.

Legal Representation

Astellas was represented by Alexandra M. Joyce and Daniel M. Silver of McCarter & English LLP, a firm with a well-established Delaware patent litigation practice frequently engaged in pharmaceutical ANDA disputes.

Renata and Somerset were represented by Dominick T. Gattuso of Heyman Enerio Gattuso & Hirzel, LLP, a Delaware-based litigation boutique known for IP and commercial matters.

Litigation Timeline & Procedural History

The case was filed in the U.S. District Court for the District of Delaware — the dominant venue for Hatch-Waxman pharmaceutical patent litigation in the United States. Delaware’s concentration of experienced IP judges, established local patent rules, and predictable scheduling orders make it the strategic first choice for branded pharmaceutical plaintiffs asserting ANDA-related infringement.

At 68 days from filing to closure, this case falls well short of the typical 30-month Hatch-Waxman litigation cycle. No claim construction hearing, summary judgment motion, or trial record appears in the available data, indicating the parties reached resolution at the earliest stages of litigation — before significant procedural milestones were joined.

This compressed timeline suggests both parties recognized early that a negotiated license served their respective commercial interests more efficiently than protracted litigation.

The Verdict & Legal Analysis

Outcome: Settlement and Dismissal Without Prejudice

The case resolved through a Settlement and License Agreement executed by all parties — Astellas Pharma, Inc., Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc., Renata Limited, and Somerset Therapeutics, LLC. Pursuant to the stipulation filed with the court:

• All claims related to the four Patents-in-Suit were dismissed without prejudice in Civil Action No. 25-1383
• The court was requested to retain jurisdiction over the matter — a standard provision enabling enforcement of the underlying settlement agreement if disputes arise
• Each party bears its own costs and attorneys’ fees, consistent with negotiated resolution rather than adjudicated liability

No damages award was issued, and no injunctive relief ruling was entered. The specific terms of the Settlement and License Agreement — including any royalty structure, market entry dates, or licensing conditions — were not publicly disclosed, which is standard practice in pharmaceutical patent settlements.

Verdict Cause Analysis

The underlying cause of action was patent infringement under the Hatch-Waxman framework. When a generic manufacturer files an ANDA with a Paragraph IV certification — asserting that a branded company’s patents are invalid, unenforceable, or not infringed — the branded company has 45 days to file suit, triggering an automatic 30-month stay of FDA approval.

Astellas’ assertion of four distinct patents suggests a deliberate portfolio layering strategy: even if one patent were successfully challenged on validity or non-infringement grounds, the remaining patents maintain litigation leverage and extend the exclusivity defense.

The fact that Renata and Somerset filed counterclaims (referenced in the settlement stipulation) indicates the defendants pursued invalidity and/or non-infringement challenges — standard defensive postures in ANDA litigation. However, these counterclaims were resolved as part of the global settlement without judicial determination on the merits.

Legal Significance

Because the case settled before claim construction or any merits ruling, it carries no direct precedential value regarding the scope or validity of the asserted patents. The four patents-in-suit remain active and fully enforceable — a critical point for any other ANDA filer targeting Myrbetriq® generics.

The dismissal without prejudice is notable: Astellas preserves its right to reassert these patents against Renata should the terms of the Settlement and License Agreement be violated or should new ANDA filings arise outside the scope of the agreement.

Strategic Takeaways

For Patent Holders:
Astellas’ multi-patent assertion — spanning four patents across multiple application families — exemplifies best-practice portfolio construction for pharmaceutical exclusivity defense. Layered patent estates increase settlement leverage and complicate invalidity challenges.

For Accused Infringers:
Renata’s counterclaimant posture and eventual license negotiation reflects a pragmatic defense strategy. When litigation costs, regulatory uncertainty, and market entry timing align, a structured license agreement can deliver earlier market access than years of contested litigation.

For R&D Teams:
Any company developing formulations that could compete with Myrbetriq® should conduct rigorous Freedom to Operate (FTO) analysis covering all four asserted patents, as the settlement — not a court ruling — leaves their validity and scope legally intact.

Industry & Competitive Implications

The Astellas v. Renata settlement reflects broader trends in pharmaceutical patent litigation strategy. Multi-patent portfolios covering the same product from different angles — formulation, release mechanism, dosage form — have become the standard defensive architecture for branded drug companies facing generic entry.

Delaware’s role as the premier ANDA litigation venue continues unabated. The combination of experienced judges, streamlined patent procedures, and predictable scheduling reinforces why virtually every major branded pharmaceutical company files its Hatch-Waxman suits there.

The rapid 68-day resolution also signals that early-stage settlements are increasingly common as both parties weigh the cost-benefit calculus of protracted patent trials. For Renata and Somerset, a license agreement provides a defined path to market. For Astellas, it preserves revenue-generating exclusivity without the uncertainty of trial.

Companies in the overactive bladder therapeutic space — and those developing controlled-release oral solid dosage forms broadly — should monitor Astellas’ ongoing patent portfolio for additional ANDA-related assertions, as the four patents remain live and commercially significant.